ES3057099T3 - Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome - Google Patents

Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Info

Publication number
ES3057099T3
ES3057099T3 ES22700096T ES22700096T ES3057099T3 ES 3057099 T3 ES3057099 T3 ES 3057099T3 ES 22700096 T ES22700096 T ES 22700096T ES 22700096 T ES22700096 T ES 22700096T ES 3057099 T3 ES3057099 T3 ES 3057099T3
Authority
ES
Spain
Prior art keywords
mds
tasquinimod
pharmaceutical salt
acceptable pharmaceutical
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22700096T
Other languages
English (en)
Spanish (es)
Inventor
Manja Wobus
Katja Sockel
Martin Bornhäuser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of ES3057099T3 publication Critical patent/ES3057099T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES22700096T 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome Active ES3057099T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21201509 2021-10-07
EP21205665 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
ES3057099T3 true ES3057099T3 (en) 2026-02-26

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22700096T Active ES3057099T3 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US20240091215A1 (enExample)
EP (1) EP4277628B1 (enExample)
JP (1) JP7837338B2 (enExample)
KR (1) KR20230133317A (enExample)
AU (1) AU2022208424A1 (enExample)
CA (1) CA3204120A1 (enExample)
ES (1) ES3057099T3 (enExample)
IL (1) IL304232A (enExample)
MX (1) MX2023008016A (enExample)
PL (1) PL4277628T3 (enExample)
WO (1) WO2022152902A1 (enExample)
ZA (1) ZA202307855B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240012436A (ko) 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome
CN122272585A (zh) * 2026-05-08 2026-06-26 吉林大学 他喹莫德在制备用于调控淋巴管炎症反应的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
SI3016512T1 (sl) 2013-07-05 2020-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Topni CD33 za zdravljenje mielodisplastičnih sindromov (MDS)
SG11201607083VA (en) 2014-02-28 2016-09-29 Incyte Corp Jak1 inhibitors for the treatment of myelodysplastic syndromes
EP3041472B1 (en) * 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017009854B1 (pt) 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
JP2019127473A (ja) 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
US20240091215A1 (en) 2024-03-21
EP4277628A1 (en) 2023-11-22
AU2022208424A9 (en) 2024-05-09
EP4277628C0 (en) 2025-09-24
CA3204120A1 (en) 2022-07-21
AU2022208424A1 (en) 2023-08-24
ZA202307855B (en) 2025-12-17
MX2023008016A (es) 2023-07-13
EP4277628B1 (en) 2025-09-24
KR20230133317A (ko) 2023-09-19
JP7837338B2 (ja) 2026-03-30
JP2024503372A (ja) 2024-01-25
PL4277628T3 (pl) 2026-02-09
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
Chen et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma
US20240091215A1 (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
US20220168333A1 (en) Combination Treatment for Hematological Cancers
ES2418433T3 (es) Modulación de receptores de catecolaminas
Urs et al. Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression
ES3037361T3 (en) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
Yamaguchi et al. Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation
US12622898B2 (en) Methods and compositions for improving bone marrow hematopoietic functions
US9199028B2 (en) Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
HK40100349B (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
HK40100349A (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
US20180042994A1 (en) Methods of treating diseases related to mitochondrial function
CN116887844A (zh) 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
EP4342479A1 (en) Composition containing function-reinforced stem cell for prevention or treatment of atopic dermatitis
WO2019049939A1 (en) METHODS AND COMPOSITIONS FOR PROPAGATION OF CELLS
CN105030749B (zh) 丙戊酸钠在制备预防和治疗移植物抗宿主病药物中的应用
US9220706B2 (en) Inhibition of leukemic stem cells by PP2A activating agents
US20110256236A1 (en) Enhancement of the Anti-Leukemic Effect of Thalidomide
CN116509834A (zh) 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用
KR20260027177A (ko) Mpn 치료에 사용하기 위한 퀴놀린 카르복사미드
Michelozzi The role of the bone marrow microenvironment in aplastic anaemia and acute myeloid leukaemia: from pathogenesis to chemoresistance
ES2370203T3 (es) Método de control de la proliferación y diferenciación de células progenitoras y madre.
Shin et al. Quercetin 3-O-β-(2”-galloyl)-rhamnopyranoside promotes the differentiation of hematopoietic stem cells or early progenitor cells into erythroid lineage in mice
Lock et al. Myelofibrosis with myeloid metaplasia.
Cheloni Chronic myeloid leukaemia stem cells are sensitive to the pharmacological inhibition of hypoxia inducible factor-1a